Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7002987 | 1.00 | HPGD (0.49) | HPGDGAAHSD17B10EPHX1PREP | |
| SCHEMBL1202111 | 1.00 | HPGD (0.49) | HPGDGAAHSD17B10EPHX1PREP | |
| SCHEMBL357043 | 0.95 | HSD17B10 (0.52) | HPGDHSD17B10EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL178721 | 0.95 | HSD17B10 (0.52) | HPGDHSD17B10EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL357042 | 0.95 | HSD17B10 (0.52) | HPGDHSD17B10EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL31539240 | 0.88 | HPGD (0.48) | HPGDHSD17B10EPHX1PREPSMN1; SMN2 | |
| SCHEMBL27618621 | 0.88 | PREP (0.42) | HPGDGAAHSD17B10EPHX1PREP | |
| SCHEMBL4175218 | 0.87 | CHRM2 (0.44) | HPGDHSD17B10EPHX1PREPSMN1; SMN2 | |
| SCHEMBL489128 | 0.87 | CHRM2 (0.44) | HPGDHSD17B10EPHX1PREPSMN1; SMN2 | |
| SCHEMBL489126 | 0.87 | CHRM2 (0.44) | HPGDHSD17B10EPHX1PREPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| EP-4559912-A1 | SULFUR-CONTAINING HETEROAROMATIC RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2025-05-28 | — | — | EP | disclosed |
| CN-119522220-A | Sulfur-containing heteroaromatic compounds, pharmaceutical compositions thereof and uses thereof | 苏州信诺维医药科技股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| CN-118974020-A | Substituted 3-aminoindazole derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024017306-A1 | SULFUR-CONTAINING HETEROAROMATIC RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| US-20230365589-A1 | NOVEL AMINE DERIVATIVES | Sumitomo Pharma Co., Ltd. (JP) | 2023-11-16 | — | — | US | disclosed |
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| EP-3650449-B1 | FXR RECEPTOR AGONIST | XUANZHU BIOPHARMACEUTICAL CO LTD (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010124055-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100179114-A1 | S-Isomer of 2- piperidine and Other Dermal Anesthetic Agents | BRIDGE PHARMA, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7718674-B2 | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine | BRIDGE PHARMA, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| WO-2008024371-A2 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1138679-B1 | HYDRONAPHTHO 2,3-c]FURAN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAGAMI CHEM RES (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-6392059-B1 | THERAPY FOR ALZHEIMER'S DISEASE | SAGAMI CHEMICAL REASEARCH CENTER (JP) | 2002-05-21 | — | — | US | disclosed |
| EP-1138679-A1 | HYDRONAPHTHO 2,3-c]FURAN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179114-A1 | S-Isomer of 2- piperidine and Other Dermal Anesthetic Agents | TRPA1, OPRL1, OPRM1 | HPGD 1248/4885GAA 4260/4885HSD17B10 3175/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | HPGD 2141/4885GAA 3479/4885HSD17B10 3713/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | HPGD 223/4885GAA 2545/4885HSD17B10 863/4885 |
| US-20230365589-A1 | NOVEL AMINE DERIVATIVES | DYRK2, DYRK1A, DYRK1B | HPGD 4077/4885GAA 1855/4885HSD17B10 3181/4885 |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | CDK4, CDKL4, CDK2 | HPGD 561/4885GAA 3166/4885HSD17B10 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.